Progenics Pharmaceuticals (PGNX) stock price, revenue, and financials

Progenics Pharmaceuticals market cap is $364.5 m, and annual revenue was $15.62 m in FY 2018

$364.5 M

PGNX Mkt cap, 10-Jun-2019
Progenics Pharmaceuticals Net income (Q2, 2019)-19.7 M
Progenics Pharmaceuticals EBIT (Q2, 2019)-19.1 M
Progenics Pharmaceuticals Cash, 30-Jun-201984.8 M
Progenics Pharmaceuticals EV316 M

Progenics Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

7.9m8.7m69.4m11.7m15.6m

R&D expense

33.9m28.2m37.6m42.6m35.1m

General and administrative expense

14.8m18.2m23.4m24.9m29.4m

Operating expense total

50.8m48.0m56.3m70.1m82.0m

Depreciation and amortization

939.0k

EBIT

(43.0m)(39.3m)13.1m(58.4m)(66.4m)

EBIT margin, %

(547%)(453%)19%(499%)(425%)

Interest expense

493.0k4.3m

Interest income

46.0k52.0k

Income tax expense

362.0k133.0k(1.8m)11.7m1.6m

Net Income

(42.6m)(39.1m)10.7m(51.0m)(67.7m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

867.0k1.8m1.5m248.0k1.9m1.4m2.5m8.5m53.9m2.3m2.7m3.2m3.9m5.3m4.3m

Cost of goods sold

493.0k

R&D expense

7.9m6.9m7.8m6.5m6.4m6.8m9.1m8.0m9.8m10.0m10.3m8.1m9.3m8.1m12.4m13.1m

General and administrative expense

3.1m3.9m4.3m3.6m6.0m4.4m5.8m5.6m7.2m5.7m6.0m6.7m7.6m7.1m9.2m14.6m

Operating expense total

11.4m11.1m12.6m10.1m13.6m11.4m15.2m14.2m17.6m17.6m17.0m15.6m18.2m30.4m22.5m29.1m

Depreciation and amortization

179.0k144.0k133.0k129.0k137.0k

EBIT

(10.5m)(9.3m)(11.1m)(10.3m)(11.7m)(10.0m)(12.7m)(5.7m)36.2m(15.3m)(14.3m)(12.4m)(14.3m)(25.0m)(18.2m)(19.1m)

EBIT margin, %

(1212%)(514%)(751%)(4140%)(604%)(718%)(519%)(67%)67%(650%)(530%)(389%)(370%)(471%)(426%)

Interest expense

1.1m1.0m1.0m930.0k762.0k

Interest income

12.0k12.0k13.0k12.0k11.0k10.0k43.0k54.0k79.0k

Pre tax profit

(15.3m)(25.8m)(19.7m)

Income tax expense

1.0k96.0k1.5m

Net Income

(10.5m)(9.3m)(11.1m)(10.3m)(11.7m)(10.0m)(12.7m)(5.7m)36.3m(16.4m)(15.4m)(13.4m)(15.2m)(24.4m)(18.7m)(19.7m)

Progenics Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

65.9m119.3m74.1m138.9m90.6m137.7m

Accounts Receivable

2.9m109.0k3.5m4.9m4.0m3.8m

Inventories

Current Assets

70.7m121.9m83.3m148.1m96.9m144.1m

PP&E

2.4m4.8m4.1m3.9m

Goodwill

7.7m7.7m13.1m13.1m13.1m13.1m

Total Assets

114.5m161.0m131.3m199.0m146.0m169.5m

Accounts Payable

6.5m6.6m9.5m567.0k3.4m444.0k

Short-term debt

Current Liabilities

6.6m6.7m9.7m16.4m15.4m23.4m

Long-term debt

47.2m39.2m

Total Debt

47.2m39.2m

Total Liabilities

35.6m40.6m94.2m82.5m68.4m

Additional Paid-in Capital

548.5m589.8m594.5m598.1m609.8m713.0m

Retained Earnings

(466.7m)(462.3m)(501.4m)(490.6m)(541.6m)(609.2m)

Total Equity

79.0m124.9m90.7m104.8m63.5m101.1m

Debt to Equity Ratio

0.7 x

Debt to Assets Ratio

0.3 x

Financial Leverage

1.5 x1.3 x1.4 x1.9 x2.3 x1.7 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

75.6m94.0m85.3m99.3m90.4m65.7m60.1m98.9m126.3m114.0m98.3m83.4m87.5m148.9m109.6m84.8m

Accounts Receivable

754.0k817.0k1.5m1.4m1.5m2.4m3.6m3.9m2.1m2.7m2.6m3.5m3.8m5.8m4.9m10.6m

Current Assets

77.6m97.7m88.8m103.4m97.9m73.2m69.0m106.6m132.1m119.9m102.6m91.8m93.5m156.9m117.6m100.2m

PP&E

2.3m3.7m3.9m4.7m4.6m4.4m3.9m4.1m4.0m6.1m7.0m

Goodwill

7.7m7.7m7.7m7.7m7.7m13.1m13.1m13.1m13.1m13.1m13.1m13.1m13.1m13.1m17.8m17.8m

Total Assets

122.5m141.4m132.4m142.4m136.9m121.0m118.2m156.9m182.9m170.5m152.9m140.7m142.5m182.4m164.2m152.8m

Accounts Payable

5.9m4.0m4.2m6.5m9.8m1.5m1.1m1.1m971.0k1.1m1.1m1.6m548.0k629.0k564.0k272.0k

Current Liabilities

6.1m4.1m4.4m6.6m9.9m11.4m13.4m13.8m14.4m16.5m13.1m14.3m14.8m16.5m24.4m23.6m

Long-term debt

48.9m48.3m47.8m45.0m42.9m38.3m37.6m36.3m

Total Debt

48.9m48.3m47.8m45.0m42.9m38.3m37.6m36.3m

Total Liabilities

35.6m33.5m34.2m37.1m40.2m42.5m44.4m45.9m93.6m96.0m92.8m80.0m79.7m67.5m80.8m80.1m

Additional Paid-in Capital

547.9m586.7m588.1m592.2m593.5m595.1m596.1m597.0m598.9m600.8m601.7m619.0m635.7m712.1m714.1m724.0m

Retained Earnings

(458.1m)(476.0m)(487.1m)(484.2m)(494.2m)(514.0m)(519.7m)(483.4m)(506.9m)(523.6m)(538.9m)(555.0m)(570.1m)(594.5m)(627.9m)(647.6m)

Total Equity

86.9m107.9m98.2m105.3m96.7m78.5m73.8m111.0m89.3m74.6m60.1m60.6m62.8m114.9m83.4m72.7m

Debt to Equity Ratio

0.6 x0.7 x0.7 x0.3 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.2 x

Financial Leverage

1.4 x1.3 x1.3 x1.4 x1.4 x1.5 x1.6 x1.4 x2 x2.3 x2.5 x2.3 x2.3 x1.6 x2 x2.1 x

Progenics Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(42.6m)4.4m(39.1m)10.7m(51.0m)(67.7m)

Depreciation and Amortization

939.0k545.0k565.0k2.1m1.1m1.5m

Accounts Receivable

4.1m2.8m(3.4m)(1.3m)892.0k204.0k

Inventories

Accounts Payable

243.0k2.8m(2.9m)

Cash From Operating Activities

(36.1m)13.7m(40.1m)19.2m(53.6m)(46.8m)

Purchases of PP&E

(4.3m)(269.0k)(817.0k)

Cash From Investing Activities

3.0m1.8m(6.5m)(3.9m)(232.0k)(817.0k)

Long-term Borrowings

(5.4m)

Cash From Financing Activities

40.1m37.9m1.4m49.6m5.5m94.7m

Interest Paid

4.7m

Free Cash Flow

(36.2m)14.4m(39.8m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(34.0m)(9.3m)(12.3m)(10.3m)(22.0m)(32.0m)(12.7m)(18.3m)18.0m(16.4m)(33.0m)(48.3m)(13.4m)(28.6m)(53.0m)(18.7m)(38.4m)

Depreciation and Amortization

774.0k144.0k318.0k132.0k261.0k398.0k751.0k1.5m1.9m256.0k544.0k832.0k286.0k590.0k1.0m557.0k1.2m

Accounts Receivable

6.2m2.1m(43.0k)(1.3m)1.2m(20.0k)(403.0k)2.8m2.1m2.2m491.0k164.0k(1.8m)(1.1m)(6.8m)

Accounts Payable

1.2m733.0k770.0k402.0k557.0k527.0k(1.8m)(2.8m)(2.7m)124.0k(169.0k)

Cash From Operating Activities

(26.4m)(9.3m)(10.9m)(19.9m)(29.7m)(8.0m)(11.5m)27.3m(12.7m)(25.4m)(41.0m)(14.3m)(25.2m)(37.8m)(18.5m)(38.7m)

Purchases of PP&E

(607.0k)(2.7m)(3.3m)(145.0k)(240.0k)(263.0k)(16.0k)(502.0k)(595.0k)(491.0k)(1.8m)

Cash From Investing Activities

3.1m36.0k(51.0k)(216.0k)(228.0k)(494.0k)(2.4m)(2.9m)(113.0k)(203.0k)(226.0k)(16.0k)(502.0k)(595.0k)(8.5m)(10.1m)

Long-term Borrowings

(2.2m)(3.4m)(1.0m)(2.6m)

Cash From Financing Activities

40.1m37.5m61.0k116.0k1.0m11.0k510.0k232.0k564.0k491.0k9.5m22.6m96.7m(1.0m)(2.3m)

Interest Paid

1.1m2.1m

Free Cash Flow

(26.5m)(9.3m)(10.9m)(20.1m)(29.9m)

Progenics Pharmaceuticals Ratios

USDY, 2019

EV/EBIT

-22.3 x

EV/CFO

-11 x

Financial Leverage

2.1 x

Progenics Pharmaceuticals Employee Rating

2.011 votes
Culture & Values
2.6
Work/Life Balance
2.7
Senior Management
2.0
Salary & Benefits
2.9
Career Opportunities
2.0
Source